Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$1.03B+74.06%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gael Touya
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 14,000
- Beta
- 0.38
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.89
Financials
Revenue
$1.03B+74.1%Net Income
$87.57M+64.9%EBITDA
$207.78M+68.4%Free Cash Flow
$45.92M-44.5%EPS (diluted)
$1.36+65.9%Shares Outstanding (diluted)
64.50M-0.3%Operating Expenses
$325.29MCash & Debt
$197.27MReturn of Capital
$80.61MRevenue by Segment (annual)
$3.05BDividend per Share
$0.48Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.78B | $392.79M | $5.97 |
| 2024 | $3.58B | $374.54M | $5.65 |
| 2023 | $3.49B | $284.49M | $4.34 |
| 2022 | $3.32B | $239.29M | $3.66 |
| 2021 | $3.23B | $244.10M | $3.72 |
| 2020 | $2.93B | $214.04M | $3.32 |
| 2019 | $2.86B | $242.20M | $3.81 |
| 2018 | $2.76B | $194.75M | $3.12 |
| 2017 | $2.47B | $220.03M | $3.52 |
| 2016 | $2.33B | $205.59M | $3.27 |
| 2015 | $2.32B | $199.35M | $3.19 |
| 2014 | $2.60B | $191.66M | $2.95 |
| 2013 | $2.52B | $171.99M | $2.60 |
| 2012 | $2.33B | $162.61M | $2.45 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ATR's reported EPS growth of 7.1% a year over 13 years.
- EPS in 5 years
- $8.42
- Implied price
- $168.39
- Return from $120.61
- 6.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $83.72 — -30.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -2.9% | -9.8% | -6.2% | -3.1% | -0.3% | 2.1% |
| 2.1% | -5.1% | -1.3% | 1.9% | 4.8% | 7.4% |
| 7.1% | -0.5% | 3.5% | 6.9% | 9.9% | 12.7% |
| 12.1% | 4.2% | 8.3% | 11.9% | 15.1% | 17.9% |
| 17.1% | 8.8% | 13.1% | 16.9% | 20.2% | 23.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
52+30.00%Social Signal Score
Mentions (9)
- Newszacks.com·23h ago·Neutral
AptarGroup (ATR) Loses 5.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner AptarGroup (ATR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
View source ↗ - Newszacks.com·10d ago·Negative
3 Packaging Stocks Worth Watching Despite Industry Pressure Although weak demand and tariffs cloud the Zacks Containers - Paper and Packaging industry's near-term outlook, AVY, ATR and KRT are navigating the challenges well.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (Marketaux)gurufocus.com·21d ago·Positive
ATR Looks 22.3% Undervalued on GF Value™ Amid Strong Dividend Profile On September 14, 2026, AptarGroup</e[+191 characters]
View source ↗ - News (RSS)seekingalpha·26d ago·Positive
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·34d ago·Negative
…rbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings reinforce results…
View source ↗ - News (RSS)economictimes·35d ago·Neutral
'Fly91 close to ordering at least 20 ATR turboprops'
View source ↗ - Newsprnewswire.com·53d ago·Negative
Atrium Therapeutics Reports Second Quarter 2026 Financial Results -- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted t…
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $1.48 per share
Typical surprise +3.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$1.42 vs $1.35beat
- Thu, Apr 30$1.19 vs $1.15beat
- Thu, Feb 5$1.25 vs $1.24beat
- Thu, Oct 30$1.62 vs $1.57beat
- Thu, Jul 31$1.66 vs $1.58beat
- Thu, May 1$1.20 vs $1.16beat
Estimates and results for ATR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ATR officers and directors.
- Bought
- —
- Sold
- $5.2m
0 trades
15 trades
- Vinczeller Shielasold
- Touya Gaelsold
- Touya Gaelsold
- Prieur Marcsold
- Prieur Marcsold
- Tanda Stephan B.sold
- Tlili Hedisold
- Prieur Marcsold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (31d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (25d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 10, 2025 (21d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2025 (32d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2025 (21d later)Buy$15,001 - $50,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 18, 2024 (23d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 14, 2023 (43d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 14, 2023 (43d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 19, 2022 (42d later)Buy$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 19, 2022 (42d later)Buy$50,001 - $100,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (22d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Oct 21, 2019 (40d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Oct 21, 2019 (38d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Aug 29, 2019 (48d later)Sell$1,001 - $15,000
- Elizabeth Pannill Fletcherhouse · TX07 · disclosed Apr 23, 2019 (56d later)Sell$1,001 - $15,000
- Brad Schneiderhouse · IL10 · disclosed Apr 6, 2019 (32d later)Sell$250,001 - $500,000
- Brad Schneiderhouse · IL10 · disclosed Feb 17, 2019 (12d later)Buy$250,001 - $500,000
- David McKinleyhouse · WV01 · disclosed Jan 9, 2019 (23d later)Sell$15,001 - $50,000
- David McKinleyhouse · WV01 · disclosed Jan 9, 2019 (23d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.